ISRG Intuitive Surgical (NASDAQ): $477.68 intraday on 13 Mar 2026, AI stock outlook

ISRG stock trades at $477.68 intraday on 13 Mar 2026, down $15.19 (-3.08%) as volume runs at 325,454 shares. The drop keeps shares below the 50-day average of $519.34 and near the day low of $476.62, while the market cap is about $170.20B. We look at valuation, recent news, technical signals, and Meyka AI forecasts to frame the opportunity and risk for US NASDAQ investors.

ISRG stock snapshot: intraday price, volume and market context

Intuitive Surgical, Inc. (ISRG) on NASDAQ is trading at $477.68 with a day range of $476.62–$482.73 and average volume of 1,923,981. The stock is -14.72% YTD and sits well below the 50-day average of $519.34 and the 200-day average of $511.95. Recent insider selling was reported in the filings and was noted in the market Investing.com report.

ISRG earnings, valuation and fundamentals

Intuitive reported EPS of $7.89 trailing twelve months and a price/earnings near 60.74. Revenue and net income grew in 2024 by 17.24% and 29.18%, respectively, showing solid top-line momentum. Key ratios: price/sales 17.07, price/book 9.63, and free cash flow per share $7.02, supporting a premium valuation versus peers in Healthcare.

Meyka AI grade and forecast for ISRG stock

Meyka AI rates ISRG with a score out of 100: 79.76 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, analyst consensus, and forecasts. Meyka AI’s forecast model projects monthly $438.35 (-8.23%), quarterly $485.77 (+1.70%), and yearly $585.45 (+22.56%) versus the current price $477.68. Forecasts are model-based projections and not guarantees.

Technical view and trading signals for ISRG stock

Momentum indicators show near-oversold conditions: RSI 37.61, CCI -156.82, and MACD slightly negative. ATR is 13.48, and Bollinger lower band sits around $479.10, implying higher intraday volatility. Traders may watch $476.62 intraday support and $494.90 (BB middle) as initial resistance levels.

Risks and growth opportunities for ISRG investment

Upside is tied to adoption of surgical robotics and recurring consumables revenue; full-year forecast implies ~22.56% upside to Meyka’s one-year target. Risks include the stretched valuation, P/E near 60.74, lower procedure volumes if hospitals tighten budgets, and competitive pressure in robotic and diagnostic systems. The next earnings date is 2026-04-21, a potential catalyst for volatility.

Analyst sentiment, recent news and market signals

Street coverage shows 16 Buys, 4 Holds, 2 Sells with a consensus score near neutral. Recent coverage flagged strong procedure growth and recurring revenue strength; see the company quote at CNBC. Institutional flows remain active, including recent position adjustments reported by filings and market trackers.

Final Thoughts

ISRG stock trades at $477.68 intraday on NASDAQ with a mix of growth strength and valuation risk. Financials show robust free cash flow per share $7.02, EPS $7.89, and strong margins, but P/E near 60.74 demands growth to justify the multiple. Meyka AI’s model projects a one-year target of $585.45, implying +22.56% from the current price, while the monthly model shows a short-term pullback to $438.35 (-8.23%). Investors should weigh the growth outlook and recurring revenue model against near-term volatility and stretched multiples. For real-time tracking and model updates visit our Meyka AI-powered market analysis page for ISRG and monitor the April 21 earnings date for fresh catalysts. Forecasts are projections, not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.